Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 32nd Prioritisation – 3rd quarter 2017. HSO: 32nd Prioritisation.
|PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader|
For the 32 prioritisation (August 2017), 10 drugs were filtered out of 366 identified and were sent to
prioritisation. Of these, 5 drugs were ranked as "highly relevant" by the expert panel, 5 as "relevant" and none as "not relevant". For "highly relevant" drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.
|Item Type:||DSD: Horizon Scanning in Oncology|
|Subjects:||WB Practice of medicine > WB 300-962 Therapeutics|
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
|Series Name:||HSO: 32nd Prioritisation|
|Deposited on:||23 Aug 2017 12:46|
|Last Modified:||23 Aug 2017 12:46|
Repository Staff Only: item control page